Routes to enhanced HIV neuropathogenesis through expression of subclinical levels of endogenous amyloid-beta
Routes to enhanced HIV neuropathogenesis through expression of subclinical levels of endogenous amyloid-beta
批准号:
10206405
负责人:
OTTAVIO ARANCIO
金额:
$86.85万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-08-15 至 2022-02-28
关键词:
AffectAgeAgingAlzheimer&aposs DiseaseAlzheimer&aposs disease modelAlzheimer&aposs disease pathologyAmyloid beta-ProteinAmyloid beta-Protein PrecursorApoptosisBioinformaticsBiologicalBiological AssayBiological ProcessBrainBrain DiseasesBrain regionCREB1 geneCell Culture TechniquesCharacteristicsCognition DisordersCognitiveCorpus striatum structureDefectDevelopmentDiseaseDoseElementsFunctional disorderGene ExpressionGene ProteinsGenesGoalsHIVHIV InfectionsHippocampus (Brain)HumanInfectionInjuryInterdisciplinary StudyJointsKnock-in MouseKnowledgeLaboratoriesLaboratory miceLate Onset Alzheimer DiseaseLearningLearning DisabilitiesLibrariesLong-Term PotentiationMemoryMemory impairmentModelingMolecularMusMyeloid CellsNeurocognitive DeficitNeuronal PlasticityNeuronsNeuropathogenesisNuclear RNAOnset of illnessOverlapping GenesPathogenesisPathogenicityPathologyPathway interactionsPatientsPrefrontal CortexPresenile Alzheimer DementiaProcessProteinsProteolysisReportingRiskRodentRoleRouteSenile PlaquesSeveritiesSideSiteSliceSpecificitySynapsesSynaptic plasticitySystemSystems BiologyTestingTranscriptTransgenesTransgenic MiceVirusWNT Signaling PathwayWild Type MouseWorkage related neurodegenerationamyloid pathologyamyloid precursor protein processingantiretroviral therapybrain cellcalmodulin-dependent protein kinase IIcell typeexperimental studymouse modelmutantneuropathologynext generationoAβoverexpressionpre-clinicalsynergismtau Proteinstherapy developmenttranscriptometranscriptome sequencing
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
We propose a collaborative project between HIV and Alzheimer's Disease (AD) laboratories to investigate
potential synergy between HIV infection and amyloid β (Aβ), a key hallmark of aging and AD, in promoting
memory impairment. Half of HIV patients on antiretroviral therapy develop neurocognitive impairments (NCI)
despite low HIV brain burdens. Age is the most consistent factor affecting NCI progression. We reproduced
HIV-NCI pathogenesis in conventional mice infected with EcoHIV, a mouse-tropic HIV. The MPI in the project,
Dr. Arancio, reported that non-synaptotoxic doses of exogenous oAβ and Tau, another AD hallmark, cooperate
in synaptic dysfunction and memory impairment in mice, suggesting that AD proteins have pathogenic potential
at their subclinical concentrations. Our joint preliminary results indicate that similar cooperation occurs after
administration of a suboptimal oAβ dose to EcoHIV infected mice or in culture or after EcoHIV infection of
cognitively normal APP/PS1 mice, a model of endogenous oAβ accumulation followed by AD pathology. We
propose that HIV and subclinical oAβ processes cooperate in disrupting synaptic plasticity to exacerbate HIV-
NCI beyond each agent alone. The Specific Aims are to: 1) Define specifics of enhanced HIV-NCI pathogenesis
in EcoHIV infected mice accumulating endogenous oAβ prior to showing AD pathology. (A) optimize the onset
of memory deficits with EcoHIV infection in preclinical APP/PS1 mice; (B) determine HIV-NCI severity at disease
onset by infected oAβ expressing mice for. If aging hAPP-KI mice, a late onset AD model, reproduce findings in
APP/PS1 it will be used in subsequent studies. 2) Using a model from Aim 1, we will conduct next generation
RNA sequencing (RNA-seq) in infected mice upon reaching HIV disease state compared to controls to: A)
generate transcriptome from hippocampus (HPC), prefrontal cortex (PFC), and striatum (STR), and define
biological processes specifically associated with memory defects caused jointly by HIV and oAβ; B) confirm
some transcripts by RT-QPCR in HPC and STR extracts; and C) conduct limited nuclear-RNA-seq analysis in
HPC to assign altered HIV-oAβ processes/transcripts to specific cell types. 3) Study molecular mechanisms
responsible for promoting HIV-NCI pathogenesis in the setting of naturally produced subclinical levels of human
oAβ in mice. (A) since both HIV and Aβ disturb wnt signaling and cause dendritic pruning, examine how HIV
infection of myeloid cells works with Aβ in dysregulating Wnt function in dendritic integrity. B) since EcoHIV
downmodulates CaMKII and CREB in mice study potential Aβ-HIV convergence in oAβ dysregulation of the
CREB role in synaptic strengthening. Studies will include EcoHIV infection of moderate and late onset AD mice,
tests of learning and memory, HPC long-term potentiation HPC synaptodendritic integrity, apoptosis, APP
processing, and amyloid pathology system and brain HIV burdens, bioinformatics of mouse brain and select cell
types, and use of control non-neuropathogenic EcoHIV∆ Nef.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1038/s41598-023-33491-7
发表时间:
2023-04-21
期刊:
SCIENTIFIC REPORTS
影响因子:
4.6
作者:
[Kim, Boe-Hyun, Hadas, Eran, Kelschenbach, Jennifer, Chao, Wei, Gu, Chao-Jiang, Potash, Mary Jane, Volsky, David J.]
通讯作者:
Volsky, David J.
Routes to enhanced HIV neuropathogenesis through expression of subclinical levels of endogenous amyloid-beta
-
批准号:10415699
-
项目类别:
-
资助金额:$247.5万
-
财政年份:2022
-
负责人:OTTAVIO ARANCIO
-
依托单位:
Chaperome networks in Alzheimer's disease
-
批准号:10613466
-
项目类别:
-
资助金额:$118.32万
-
财政年份:2021
-
负责人:OTTAVIO ARANCIO
-
依托单位:
Understanding the role of ECSIT in neurodegeneration and Alzheimer's Disease
-
批准号:10629415
-
项目类别:
-
资助金额:$68.04万
-
财政年份:2021
-
负责人:OTTAVIO ARANCIO
-
依托单位:
Chaperome networks in Alzheimer's disease
-
批准号:10350644
-
项目类别:
-
资助金额:$119.95万
-
财政年份:2021
-
负责人:OTTAVIO ARANCIO
-
依托单位:
Understanding the role of ECSIT in neurodegeneration and Alzheimer's Disease
-
批准号:10216433
-
项目类别:
-
资助金额:$68.04万
-
财政年份:2021
-
负责人:OTTAVIO ARANCIO
-
依托单位:
Preclinical development of a novel small molecule inhibitor of Alzheimer's disease-related cognitive impairment
-
批准号:10396647
-
项目类别:
-
资助金额:$151.68万
-
财政年份:2020
-
负责人:OTTAVIO ARANCIO
-
依托单位:
Preclinical development of a novel small molecule inhibitor of Alzheimer's disease-related cognitive impairment
-
批准号:10159812
-
项目类别:
-
资助金额:$147.29万
-
财政年份:2020
-
负责人:OTTAVIO ARANCIO
-
依托单位:
Preclinical development of a novel small molecule inhibitor of Alzheimer's disease-related cognitive impairment
-
批准号:10765513
-
项目类别:
-
资助金额:$32.9万
-
财政年份:2020
-
负责人:OTTAVIO ARANCIO
-
依托单位:
Preclinical development of a novel small molecule inhibitor of Alzheimer's disease-related cognitive impairment
-
批准号:10608172
-
项目类别:
-
资助金额:$144.48万
-
财政年份:2020
-
负责人:OTTAVIO ARANCIO
-
依托单位:
The role of SUMOylation in Tau-mediated pathology
-
批准号:10083243
-
项目类别:
-
资助金额:$38.6万
-
财政年份:2019
-
负责人:OTTAVIO ARANCIO
-
依托单位:
Exploring the contribution of viral PP2A inhibition to tau pathology in Alzheimer's disease.
-
批准号:9808829
-
项目类别:
-
资助金额:$45.48万
-
财政年份:2019
-
负责人:OTTAVIO ARANCIO
-
依托单位:
The role of SUMOylation in Tau-mediated pathology
-
批准号:10311510
-
项目类别:
-
资助金额:$38.6万
-
财政年份:2019
-
负责人:OTTAVIO ARANCIO
-
依托单位:
The Role of SUMOylation in Tau-Mediated Pathology
-
批准号:10540308
-
项目类别:
-
资助金额:$38.6万
-
财政年份:2019
-
负责人:OTTAVIO ARANCIO
-
依托单位:
ECSIT protects against neurodegeneration and Alzheimer's disease through the regulation of mitochondrial function and oxidative stress
-
批准号:9784677
-
项目类别:
-
资助金额:$61.37万
-
财政年份:2018
-
负责人:OTTAVIO ARANCIO
-
依托单位:
Extracellular tau oligomers and Alzheimer disease
-
批准号:9130081
-
项目类别:
-
资助金额:$32.8万
-
财政年份:2015
-
负责人:OTTAVIO ARANCIO
-
依托单位:
The regulation of beta-amyloid sensitivity and Alzheimer's related impairments by PP2A
-
批准号:9412910
-
项目类别:
-
资助金额:$35.0万
-
财政年份:2015
-
负责人:OTTAVIO ARANCIO
-
依托单位:
The regulation of beta-amyloid sensitivity and Alzheimer's related impairments by PP2A
-
批准号:9014573
-
项目类别:
-
资助金额:$35.0万
-
财政年份:2015
-
负责人:OTTAVIO ARANCIO
-
依托单位:
Extracellular tau oligomers and Alzheimer disease
-
批准号:9251222
-
项目类别:
-
资助金额:$32.8万
-
财政年份:2015
-
负责人:OTTAVIO ARANCIO
-
依托单位:
The regulation of beta-amyloid sensitivity and Alzheimer's related impairments by PP2A
-
批准号:9198583
-
项目类别:
-
资助金额:$35.0万
-
财政年份:2015
-
负责人:OTTAVIO ARANCIO
-
依托单位:
The regulation of beta-amyloid sensitivity and Alzheimer's related impairments by PP2A
-
批准号:8876079
-
项目类别:
-
资助金额:$35.0万
-
财政年份:2015
-
负责人:OTTAVIO ARANCIO
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: